Literature DB >> 17632696

[Pathophysiology of bone metastases in urologic carcinomas].

G Sauer1, T F E Barth, P Möller.   

Abstract

The skeletal system is the most frequent metastatic site of hematogenous spread of urologic carcinomas. Osseus metastases are classified as osteoneutral, osteolytic, osteoblastic and combinations thereof. Osteolytic metastases lead to bone resorption by activating osteoclasts, while osteoblastic metastases stimulate osteoblasts by paracrine mechanisms. The local osteoblastic effect is associated with secondary systemic bone resorption. The use of bisphosphonates is now an established supportive therapy and newer treatment strategies including targeted intervention in the pathophysiology of bone metastases and radioimmunotherapy are being applied or will be coming soon.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17632696     DOI： 10.1007/s00120-007-1519-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  11 in total

1.  Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.

Authors:  Adrienne H Brouwers; Wilhelmina C A M Buijs; Peter F A Mulders; Pieter H M de Mulder; Wim J M van den Broek; Carola Mala; Egbert Oosterwijk; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

Review 2.  Cancer and bone.

Authors:  T A Guise; G R Mundy
Journal:  Endocr Rev       Date:  1998-02       Impact factor: 19.871

Review 3.  Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.

Authors:  Robert L Vessella; Eva Corey
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 4.  Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

Authors:  K S Koeneman; F Yeung; L W Chung
Journal:  Prostate       Date:  1999-06-01       Impact factor: 4.104

5.  Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.

Authors:  Keiji Inoue; Takashi Karashima; Satoshi Fukata; Asuka Nomura; Chiaki Kawada; Atsushi Kurabayashi; Mutsuo Furihata; Yuji Ohtsuki; Taro Shuin
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

6.  Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients.

Authors:  A Wallmeroth; U Wagner; H Moch; T C Gasser; G Sauter; M J Mihatsch
Journal:  Urol Int       Date:  1999       Impact factor: 2.089

Review 7.  Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

Authors:  Fred Saad; Allan Lipton
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

Review 8.  Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.

Authors:  Allan Lipton
Journal:  J Support Oncol       Date:  2004 May-Jun

Review 9.  Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Authors:  Allan Lipton; Alejandro Colombo-Berra; Ronald M Bukowski; Lee Rosen; Ming Zheng; Gladys Urbanowitz
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

10.  Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.

Authors:  Bhavik Desai; Michael J Rogers; Meenakshi A Chellaiah
Journal:  Mol Cancer       Date:  2007-03-07       Impact factor: 27.401
View more
  1 in total

Review 1.  [Vertebral metastases of urogenital carcinomas: Diagnosis and conservative therapy].

Authors:  B Keck; M Hammon; M Uder; J Huber; P J Goebell; F Kunath; B Wullich; R H Richter
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.